News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
728,930 Results
Type
Article (43181)
Company Profile (463)
Press Release (685274)
Multimedia
Podcasts (106)
Webinars (20)
Section
Business (209109)
Career Advice (2032)
Deals (36082)
Drug Delivery (108)
Drug Development (83811)
Employer Resources (174)
FDA (16588)
Job Trends (15163)
News (353659)
Policy (33236)
Tag
Academia (2648)
Accelerated approval (18)
Adcomms (28)
Allergies (118)
Alliances (51109)
ALS (141)
Alzheimer's disease (1609)
Antibody-drug conjugate (ADC) (234)
Approvals (16661)
Artificial intelligence (416)
Autoimmune disease (72)
Automation (27)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (150)
Biotechnology (331)
Bladder cancer (133)
Brain cancer (48)
Breast cancer (494)
Cancer (3864)
Cardiovascular disease (314)
Career advice (1712)
Career pathing (34)
CAR-T (232)
CDC (44)
Cell therapy (629)
Cervical cancer (31)
Clinical research (69934)
Collaboration (1351)
Company closure (4)
Compensation (928)
Complete response letters (51)
COVID-19 (2738)
CRISPR (78)
C-suite (581)
Cystic fibrosis (136)
Data (4539)
Decentralized trials (2)
Denatured (34)
Depression (104)
Diabetes (421)
Diagnostics (6593)
Digital health (34)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (196)
Drug pricing (164)
Drug shortages (29)
Duchenne muscular dystrophy (202)
Earnings (90031)
Editorial (49)
Employer branding (21)
Employer resources (152)
Events (118929)
Executive appointments (954)
FDA (19010)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (15)
Funding (1222)
Gene editing (167)
Generative AI (31)
Gene therapy (513)
GLP-1 (904)
Government (4694)
Grass and pollen (5)
Guidances (348)
Healthcare (19188)
HIV (44)
Huntington's disease (36)
IgA nephropathy (63)
Immunology and inflammation (221)
Immuno-oncology (18)
Indications (53)
Infectious disease (2963)
Inflammatory bowel disease (178)
Inflation Reduction Act (16)
Influenza (94)
Intellectual property (188)
Interviews (315)
IPO (16896)
IRA (51)
Job creations (3710)
Job search strategy (1438)
Kidney cancer (15)
Labor market (72)
Layoffs (565)
Leadership (29)
Legal (8014)
Liver cancer (87)
Longevity (11)
Lung cancer (559)
Lymphoma (264)
Machine learning (30)
Management (59)
Manufacturing (591)
MASH (135)
Medical device (13758)
Medtech (13781)
Mergers & acquisitions (20057)
Metabolic disorders (1066)
Multiple sclerosis (133)
NASH (19)
Neurodegenerative disease (213)
Neuropsychiatric disorders (57)
Neuroscience (2605)
NextGen: Class of 2025 (6758)
Non-profit (4563)
Now hiring (58)
Obesity (509)
Opinion (260)
Ovarian cancer (134)
Pain (155)
Pancreatic cancer (168)
Parkinson's disease (235)
Partnered (27)
Patents (404)
Patient recruitment (315)
Peanut (53)
People (59640)
Pharmaceutical (86)
Pharmacy benefit managers (24)
Phase I (21961)
Phase II (30851)
Phase III (22807)
Pipeline (2704)
Policy (255)
Postmarket research (2602)
Preclinical (9424)
Press Release (67)
Prostate cancer (196)
Psychedelics (50)
Radiopharmaceuticals (275)
Rare diseases (638)
Real estate (6045)
Recruiting (70)
Regulatory (23945)
Reports (51)
Research institute (2446)
Resumes & cover letters (353)
Rett syndrome (15)
RNA editing (15)
RSV (66)
Schizophrenia (131)
Series A (205)
Series B (156)
Service/supplier (11)
Sickle cell disease (80)
Special edition (24)
Spinal muscular atrophy (154)
Sponsored (35)
Startups (3789)
State (2)
Stomach cancer (15)
Supply chain (93)
Tariffs (80)
The Weekly (70)
Vaccines (928)
Venture capital (65)
Weight loss (335)
Women's health (56)
Worklife (18)
Date
Last 7 days (712)
Last 30 days (2422)
Last 365 days (31279)
2025 (25214)
2024 (36300)
2023 (41015)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (744)
Alabama (77)
Alaska (7)
Arizona (275)
Arkansas (14)
Asia (40101)
Australia (6662)
California (9333)
Canada (2837)
China (868)
Colorado (392)
Connecticut (411)
Delaware (257)
Europe (87879)
Florida (1373)
Georgia (300)
Hawaii (2)
Idaho (60)
Illinois (731)
India (45)
Indiana (440)
Iowa (20)
Japan (319)
Kansas (121)
Kentucky (35)
Louisiana (18)
Maine (68)
Maryland (1225)
Massachusetts (6926)
Michigan (282)
Minnesota (537)
Mississippi (4)
Missouri (110)
Montana (31)
Nebraska (25)
Nevada (103)
New Hampshire (76)
New Jersey (2568)
New Mexico (30)
New York (2521)
North Carolina (1322)
North Dakota (9)
Northern California (4297)
Ohio (281)
Oklahoma (20)
Oregon (40)
Pennsylvania (1950)
Puerto Rico (18)
Rhode Island (44)
South America (1113)
South Carolina (48)
South Dakota (1)
Southern California (3580)
Tennessee (146)
Texas (1437)
United States (33970)
Utah (273)
Virginia (226)
Washington D.C. (78)
Washington State (791)
West Virginia (4)
Wisconsin (82)
Wyoming (1)
728,930 Results for "neumora therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neumora Therapeutics to Host Virtual R&D Day on October 27
October 1, 2025
·
4 min read
Press Releases
Neumora Therapeutics to Participate in Upcoming Conferences in September 2025
September 3, 2025
·
1 min read
Press Releases
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
·
9 min read
Press Releases
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
July 23, 2025
·
1 min read
Depression
Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.
January 2, 2025
·
2 min read
·
Heather McKenzie
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.
March 3, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
July 10, 2025
·
7 min read
Press Releases
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
·
10 min read
Press Releases
Neumora Therapeutics Announces Leadership Transition
February 13, 2025
·
5 min read
Press Releases
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
March 4, 2025
·
1 min read
1 of 72,893
Next
